Germany is Europe's largest pharmaceutical market, yet is recognised as having one of the most demanding health technology assessment and reimbursement policies in Europe. This meeting will discuss the global market outlook for orphan drugs, and specifically, the outlook for these drugs on the German market. Orphan drugs are drugs that treat rare diseases. Representatives from industry will discuss the latest regulatory developments affecting orphan drugs and development challenges including cost control. They will also discuss innovation in development.
